DRUG ELUTING BALLOON MARKET ANALYSIS

Drug Eluting Balloon Market, By Product Type (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon, Others), By Technology (FreePac, TransPac, EnduraCoa, Others), By End User (Hospitals, Ambulatory Surgical Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On March 1, 2024, Boston Scientific Corporation, a medical device company, announced that the U.S. Food and Drug Administration had approved the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease
In January 2023, Med Alliance SA, a medical technology company, announced that it had received conditional U.S. FDA investigational device exemption (IDE), for its its novel sirolimus-eluting balloon
In September 2022, Advanced NanoTherapies, Inc., a privately-held medical device company, announced that the U.S. Food and Drug Administration had granted the company a Breakthrough Device designation for its SirPlux Duo Drug-Coated Balloon (DCB) for coronary artery disease in vessels less than 3.0mm
In July 2021, Medtronic, a medical device company, launched Prevail drug coated balloon (DCB) Catheter in Europe, following CE (Conformité Européene) mark. It is designed to treat complex lesions with superior deliverability, rapid absorption of paclitaxel